Innovation at Glenmark
Innovation is at the heart of everything we do – from discovering novel molecules, to manufacturing effective medicines to how we operate. We practice innovation by finding new ways of doing things – big or small – and strive to enrich lives across the world.
We aim to develop innovative molecules to address evolving needs of patients, in areas where we can make a real difference. Glenmark’s drug discovery endeavours are focused on the therapeutic areas of dermatology, pain/inflammation and oncology. Our distinctive scientific capabilities have enabled us to build a strong pipeline of several first-in-class molecules - both NCEs (New Chemical Entities) and NBEs (New Biological Entities). We have also made a mark in this area by successfully out-licensing seven of our own molecules to large multinationals.
Glenmark R&D centres are well equipped to research and develop novel molecules by combining cutting-edge technology, state-of-the-art infrastructure, and the brightest minds. Glenmark’s scientists have also invented a propriety best-in-class technology platform to manufacture bispecific antibodies, BEAT®. Glenmark’s R&D team of over 800 scientists across 5 R&D centres, in India and Switzerland, are committed to identify cures for unmet needs that matter most.